{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:42:35Z","timestamp":1758588155937,"version":"3.44.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T00:00:00Z","timestamp":1536710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.transproceed.2018.08.050","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T03:35:07Z","timestamp":1536291307000},"page":"3283-3295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prolonged-Release vs Immediate-Release Tacrolimus Capsules in Black vs White Kidney Transplant Patients: A Post Hoc Analysis of Phase III Data"],"prefix":"10.1016","volume":"50","author":[{"given":"J.J.","family":"Schwartz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Elsouda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Undre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.S.A.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2018.08.050_bib1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/ctr.12294","article-title":"Long-term outcomes in African American kidney transplant recipients under contemporary immunosuppression: a four-yr analysis of the Mycophenolic acid Observational REnal transplant (MORE) study","volume":"28","author":"Narayanan","year":"2014","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2018.08.050_bib2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/TP.0000000000001119","article-title":"Overall graft loss versus death-censored graft loss: unmasking the magnitude of racial disparities in outcomes among US kidney transplant recipients","volume":"101","author":"Taber","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.08.050_bib3","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/ndt\/gfp530","article-title":"Black renal transplant recipients have poorer long-term graft survival than CYP3A5 expressers from other ethnic groups","volume":"25","author":"Ng","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2018.08.050_bib4","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/TP.0b013e318277438f","article-title":"Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression","volume":"95","author":"Narayanan","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.08.050_bib5","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJM199209173271203","article-title":"Racial differences in the survival of cadaveric renal allografts. Overriding effects of HLA matching and socioeconomic factors","volume":"327","author":"Butkus","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2018.08.050_bib6","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S0272-6386(99)70397-5","article-title":"Racial disparities in renal transplant outcomes","volume":"34","author":"Isaacs","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.transproceed.2018.08.050_bib7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00007890-200007270-00024","article-title":"African-American renal transplant recipients experience decreased risk of death due to infection: possible implications for immunosuppressive strategies","volume":"70","author":"Meier-Kriesche","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.08.050_bib8","first-page":"3918","article-title":"Kidney graft survival rates in black cyclosporine-treated recipients","volume":"21","author":"Opelz","year":"1989","journal-title":"Collaborative Transplant Study. Transplant Proc"},{"key":"10.1016\/j.transproceed.2018.08.050_bib9","first-page":"341","article-title":"Determinants of long-term survival of adult kidney transplants: a a1999 UNOS update","author":"Gjertson","year":"1999","journal-title":"Clin Transpl"},{"key":"10.1016\/j.transproceed.2018.08.050_bib10","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1056\/NEJM200003023420901","article-title":"Improved graft survival after renal transplantation in the United States, 1988 to 1996","volume":"342","author":"Hariharan","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2018.08.050_bib11","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.2165\/11318570-000000000-00000","article-title":"African American kidney transplantation survival: the ability of immunosuppression to balance the inherent pre- and post-transplant risk factors","volume":"69","author":"Malat","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.transproceed.2018.08.050_bib12","first-page":"83","article-title":"Intrapatient variability with tacrolimus","volume":"93","author":"Cervelli","year":"2012","journal-title":"Aust J Pharm"},{"key":"10.1016\/j.transproceed.2018.08.050_bib13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/11317350-000000000-00000","article-title":"Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I","volume":"49","author":"Staatz","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.transproceed.2018.08.050_bib14","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1097\/00007890-200212150-00002","article-title":"Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement","volume":"74","author":"Macphee","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.08.050_bib15","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/00000658-200212000-00012","article-title":"A\u00a0decade of experience with renal transplantation in African-Americans","volume":"236","author":"Foster","year":"2002","journal-title":"Ann Surg"},{"key":"10.1016\/j.transproceed.2018.08.050_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000363393","article-title":"Significant racial differences in the key factors associated with early graft loss in kidney transplant recipients","volume":"40","author":"Taber","year":"2014","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.transproceed.2018.08.050_bib17","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2215\/CJN.00630805","article-title":"Role of socioeconomic status in kidney transplant outcome","volume":"1","author":"Goldfarb-Rumyantzev","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2018.08.050_bib18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.semnephrol.2009.10.009","article-title":"Disparities in kidney transplant outcomes: a review","volume":"30","author":"Gordon","year":"2010","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.transproceed.2018.08.050_bib19","first-page":"28S","article-title":"Race and kidney disease: role of social and environmental factors","volume":"94","author":"Nzerue","year":"2002","journal-title":"J\u00a0Natl Med Assoc"},{"key":"10.1016\/j.transproceed.2018.08.050_bib20","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1111\/ajt.13347","article-title":"Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody","volume":"15","author":"Wiebe","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.08.050_bib21","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/ki.2013.465","article-title":"Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure","volume":"85","author":"Sapir-Pichhadze","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.transproceed.2018.08.050_bib22","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1097\/TP.0000000000001040","article-title":"Within-patient variability in tacrolimus blood levels predicts kidney graft loss and donor-specific antibody development","volume":"100","author":"Rodrigo","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.08.050_bib23","first-page":"269","article-title":"Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation","author":"O\u2019Regan","year":"2016","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.transproceed.2018.08.050_bib24","first-page":"430","article-title":"High intrapatient tacrolimus variability is associated with worse outcomes in renal transplantation using a low-dose tacrolimus immunosuppressive regimen","author":"Whalen","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.08.050_bib25","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1111\/ajt.13803","article-title":"High intrapatient variability of tacrolimus concentrations predicts accelerated progression of chronic histologic lesions in renal recipients","volume":"16","author":"Vanhove","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.08.050_bib26","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/phar.1591","article-title":"African-American race modifies the influence of tacrolimus concentrations on acute rejection and toxicity in kidney transplant recipients","volume":"35","author":"Taber","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.transproceed.2018.08.050_bib27","doi-asserted-by":"crossref","first-page":"e83472","DOI":"10.1371\/journal.pone.0083472","article-title":"Global pharmacogenomics: distribution of CYP3A5 polymorphisms and phenotypes in the Brazilian population","volume":"9","author":"Suarez-Kurtz","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.transproceed.2018.08.050_bib28","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/ctr.12376","article-title":"Tacrolimus dose requirements in African-American and Caucasian kidney transplant recipients on mycophenolate and prednisone","volume":"28","author":"Beermann","year":"2014","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2018.08.050_bib29","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1016\/j.transproceed.2013.09.010","article-title":"African American renal transplant recipients (RTR) require higher tacrolimus doses to achieve target levels compared to white RTR: does clotrimazole help?","volume":"45","author":"Laftavi","year":"2013","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2018.08.050_bib30","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.transproceed.2004.12.222","article-title":"Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen","volume":"37","author":"Alloway","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2018.08.050_bib31","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/1524839915621545","article-title":"Communicating effectively about clinical trials with African American communities","volume":"17","author":"Tanner","year":"2016","journal-title":"Health Promot Pract"},{"key":"10.1016\/j.transproceed.2018.08.050_bib32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1600-6143.2007.01661.x","article-title":"Erratum: one-year results with extended-release tacrolimus\/MMF, tacrolimus\/MMF and cyclosporine\/MMF in de novo kidney transplant recipients","volume":"7","author":"Silva","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.08.050_bib33","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1111\/j.1600-6143.2010.03256.x","article-title":"Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized Phase III study","volume":"10","author":"Kr\u00e4mer","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.08.050_bib34","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1097\/TP.0b013e3182a203bd","article-title":"OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation","volume":"96","author":"Albano","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.08.050_bib35","unstructured":"Astagraf XL (tacrolimus, extended-release capsules) [package insert]. Northbrook, IL: Astellas Pharma US, Inc. November 2018."},{"key":"10.1016\/j.transproceed.2018.08.050_bib36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40262-013-0120-3","article-title":"The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation","volume":"53","author":"Hesselink","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.transproceed.2018.08.050_bib37","unstructured":"PROGRAF [package insert]. Northbrook, IL: Astellas Pharma US, Inc. July 2018."},{"key":"10.1016\/j.transproceed.2018.08.050_bib38","unstructured":"Envarsus (tacrolimus, extended-release tablets) [package insert]. Edison, NJ. Veloxis Pharmaceuticals, Inc. June 2015."},{"key":"10.1016\/j.transproceed.2018.08.050_bib39","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/j.1600-6143.2009.02794.x","article-title":"Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial","volume":"9","author":"Wlodarczyk","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.08.050_bib40","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/TP.0b013e3182292426","article-title":"Lower variability of tacrolimus trough concentration after conversion from Prograf to Advagraf in stable kidney transplant recipients","volume":"92","author":"Wu","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.08.050_bib41","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.transproceed.2013.11.084","article-title":"Reduced variability of tacrolimus trough level in once-daily tacrolimus-based Taiwanese kidney transplant recipients with high-expressive genotype of cytochrome P450 3A5","volume":"46","author":"Wu","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2018.08.050_bib42","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/01.TP.0000437561.31212.0e","article-title":"Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation","volume":"97","author":"Stifft","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.08.050_bib43","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1600-6143.2007.02099.x","article-title":"Long-term outcome of early steroid withdrawal after kidney transplantation in African American recipients monitored by surveillance biopsy","volume":"8","author":"Kumar","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.08.050_bib44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1034\/j.1600-6143.2002.020105.x","article-title":"Steroid-free immunosuppression in kidney transplantation: an editorial review","volume":"2","author":"Hricik","year":"2002","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.08.050_bib45","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/ctr.12763","article-title":"Pharmacokinetics of prolonged-release tacrolimus and implications for use in solid organ transplant recipients","volume":"30","author":"Tanzi","year":"2016","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2018.08.050_bib47","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A\u00a0phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria\u00a0donors (BENEFIT-EXT Study)","author":"Durrbach","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.08.050_bib48","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/ndt\/gfx075","article-title":"Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from month 3: a multicentre, randomized trial","author":"Budde","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2018.08.050_bib49","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/13557858.1997.9961813","article-title":"Why are African Americans under-represented in medical research studies? Impediments to participation","author":"Shavers-Hornaday","year":"1997","journal-title":"Ethn Health"},{"key":"10.1016\/j.transproceed.2018.08.050_bib50","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1047-2797(01)00265-4","article-title":"Racial differences in factors that influence the willingness to participate in medical research studies","author":"Shavers","year":"2002","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.transproceed.2018.08.050_bib51","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1111\/j.1600-6143.2005.01057.x","article-title":"Kidney transplant in black recipients: are African Europeans different from African Americans?","volume":"5","author":"Pallet","year":"2005","journal-title":"Am J Transplant"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113451831193X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113451831193X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:30:14Z","timestamp":1758576614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004113451831193X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S004113451831193X"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2018.08.050","relation":{},"ISSN":["0041-1345"],"issn-type":[{"type":"print","value":"0041-1345"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolonged-Release vs Immediate-Release Tacrolimus Capsules in Black vs White Kidney Transplant Patients: A Post Hoc Analysis of Phase III Data","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2018.08.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}